Histatin-5 vs Lixisenatide

Head-to-head comparison of Histatin-5 (Human histatin 5) and Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyHistatin-5Lixisenatide
CategoryDental & OralWeight Management
Full NameHuman histatin 5Exendin-4-derived GLP-1 receptor agonist
Molecular Weight3035 Da4858 Da
Half-Lifeminutes in saliva2-4 hours
Amino Acids2444
Typical Dose1-100 µM in research formulations10-20 mcg daily
RouteTopical/Oral rinseSubcutaneous
Purity≥98%≥98%
Studies Count120400
Research StatusPre-clinicalApproved

Histatin-5 Benefits

  • anti-Candida activity
  • biofilm suppression
  • mucosal wound support
  • oral innate immunity

Lixisenatide Benefits

  • postprandial glucose control
  • modest weight loss
  • appetite reduction
  • short-acting option

Histatin-5 Dosing

topical rinse or gel|short contact exposure|repeat applications in research protocols

Lixisenatide Dosing

10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day

Histatin-5 Side Effects

  • local irritation
  • proteolytic instability
  • dose-dependent cytotoxicity in vitro

Lixisenatide Side Effects

  • nausea
  • vomiting
  • hypoglycemia when combined with insulin

Research Overview

Histatin-5

Histatin-5 is a major salivary defense peptide that can kill Candida species and influence oral microbial communities. It is also investigated for wound-healing and xerostomia-associated oral infection models.

Lixisenatide

Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Histatin-5 stacks with:

chlorhexidinefluoridexylitol

Lixisenatide stacks with:

basal-insulinmeal-plan
antimicrobial-peptidecandidasalivaoral-defenseGLP-1RAshort-actingpostprandial-controlweight-loss-adjacent